pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Belrapzo
drug
save

bendamustine hydrochloride

Marketedupdated 3mo ago
by Eagle Pharmaceuticals Inc
Approved
community read0 votes

indications

investigational
DLBCL

all catalysts(0)

nothing on the calendar yet

Trials studying bendamustine hydrochloride

  • phase1Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphomaactive not recruitingn=48
  • phase2Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphomarecruitingn=23
  • phase2Isatuximab and Bendamustine in Systemic Light Chain Amyloidosiswithdrawn
  • phase3A Study of Bendamustine in the Treatment of Chinese Participants With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatmentcompletedn=102

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 26, 2029
~2.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (79)

  • Jul 29, 2042formulationUS 11707450
  • Jul 29, 2042formulationUS 11844784
  • Jul 29, 2042formulationUS 12208086
  • Jul 29, 2042formulationUS 12419867
  • Mar 15, 2033method-of-use (U-1971)US 10052385
  • Mar 15, 2033method-of-use (U-1542)US 9000021
  • Mar 15, 2033method-of-use (U-1542)US 9034908
  • Mar 15, 2033method-of-use (U-1542)US 9144568
  • Mar 15, 2033method-of-use (U-1971)US 9572887
  • Mar 15, 2033method-of-use (U-1972)US 9579384
  • Mar 15, 2033method-of-use (U-1971)US 9597397
  • Mar 15, 2033method-of-use (U-1971)US 9597398
  • Mar 15, 2033method-of-use (U-1971)US 9597399
  • Aug 11, 2031formulationUS 86097075.0y
  • Aug 11, 2031formulationUS 86097075.0y
  • Apr 26, 2031patentUS 8436190*PED4.7y
  • Apr 26, 2031patentUS 8436190*PED4.7y
  • Jan 28, 2031formulationUS 100105334.4y
  • Jan 28, 2031formulationUS 100105334.4y
  • Jan 28, 2031formulationUS 111034834.4y
  • Jan 28, 2031formulationUS 111034834.4y
  • Jan 28, 2031method-of-use (U-1971)US 118447834.4y
  • Jan 28, 2031method-of-use (U-1972)US 118447834.4y
  • Jan 28, 2031formulationUS 118722144.4y
  • Jan 28, 2031formulationUS 118722144.4y
  • Jan 28, 2031formulationUS 121382484.4y
  • Jan 28, 2031formulationUS 121382484.4y
  • Jan 28, 2031formulationUS 123502574.4y
  • Jan 28, 2031formulationUS 123502574.4y
  • Jan 28, 2031formulationUS 92658314.4y
  • Jan 28, 2031formulationUS 92658314.4y
  • Jan 28, 2031formulationUS 95727964.4y
  • Jan 28, 2031formulationUS 95727964.4y
  • Jan 28, 2031method-of-use (U-1972)US 95727974.4y
  • Jan 28, 2031method-of-use (U-1971)US 95727974.4y
  • Oct 26, 2030formulationUS 84361904.2y
  • Oct 26, 2030formulationUS 84361904.2y
  • Mar 23, 2030patentUS 8344006*PED3.6y
  • Mar 23, 2030patentUS 8344006*PED3.6y
  • Sep 26, 2029patentUS 8445524*PED3.1y
  • Sep 26, 2029patentUS 8445524*PED3.1y
  • Sep 26, 2029patentUS 8445524*PED3.1y
  • Sep 26, 2029patentUS 8445524*PED3.1y
  • Sep 26, 2029patentUS 8669279*PED3.1y
  • Sep 26, 2029patentUS 8669279*PED3.1y
  • Sep 26, 2029patentUS 8883836*PED3.1y
  • Sep 26, 2029patentUS 8883836*PED3.1y
  • Sep 26, 2029patentUS 9533955*PED3.1y
  • Sep 26, 2029patentUS 9533955*PED3.1y
  • Sep 23, 2029formulationUS 83440063.1y
  • Sep 23, 2029formulationUS 83440063.1y
  • Mar 26, 2029compositionUS 84455242.6y
  • Mar 26, 2029compositionUS 84455242.6y
  • Mar 26, 2029compositionUS 84455242.6y
  • Mar 26, 2029compositionUS 84455242.6y
  • Mar 26, 2029formulationUS 86692792.6y
  • Mar 26, 2029formulationUS 86692792.6y
  • Mar 26, 2029formulationUS 88838362.6y
  • Mar 26, 2029formulationUS 88838362.6y
  • Mar 26, 2029formulationUS 95339552.6y
  • Mar 26, 2029formulationUS 95339552.6y
  • Jul 12, 2026patentUS 8609863*PED
  • Jul 12, 2026patentUS 8609863*PED
  • Jul 12, 2026patentUS 8791270*PED
  • Jul 12, 2026patentUS 8791270*PED
  • Jul 12, 2026patentUS 8791270*PED
  • Jul 12, 2026patentUS 8791270*PED
  • Jul 12, 2026patentUS 8895756*PED
  • Jul 12, 2026patentUS 8895756*PED
  • Jan 12, 2026formulationUS 8609863
  • Jan 12, 2026formulationUS 8609863
  • Jan 12, 2026formulationUS 8791270
  • Jan 12, 2026formulationUS 8791270
  • Jan 12, 2026formulationUS 8791270
  • Jan 12, 2026formulationUS 8791270
  • Jan 12, 2026formulationUS 8791270
  • Jan 12, 2026formulationUS 8791270
  • Jan 12, 2026formulationUS 8895756
  • Jan 12, 2026formulationUS 8895756

News(0)

no news has mentioned this drug yet

brand
Belrapzo
generic
bendamustine hydrochloride
indication
B-Cell Non-Hodgkin Lymphoma
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 33m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?